Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis

Amit Verma,1 Huamin Wang,2 Bramanandam Manavathi,3 Jansina Y. Fok,1 Aman P. Mann,1 Rakesh Kumar,3 and Kapil Mehta1,4

Departments of 1Experimental Therapeutics, 2Pathology, and 3Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center; 4Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas

Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive neoplastic diseases and is virtually incurable. The molecular mechanisms that contribute to the intrinsic resistance of PDAC to various anticancer therapies are not well understood. Recently, we have observed that several drug-resistant and metastatic tumors and tumor cell lines expressed elevated levels of tissue transglutaminase (TG2). Because PDAC exhibits inherent resistance to various drugs, we determined the constitutive expression of TG2 in 75 PDAC and 12 PDAC cell lines. Our results showed that 42 of 75 (56%) PDAC tumor samples expressed higher basal levels of TG2 compared with the normal pancreatic ducts [odds ratio (OR), 2.439; P = 0.012]. The increased expression of TG2 in PDAC was strongly associated with nodal metastasis (OR, 3.400; P = 0.017) and lymphovascular invasion (OR, 3.055; P = 0.045). Increased expression of TG2 was also evident in all 12 cell lines examined. The elevated expression of TG2 in PDAC cell lines was associated with gemcitabine resistance and increased invasive potential. Overexpression of catalytically active or inactive (C277S mutant) TG2 induced focal adhesion kinase (FAK) activation and augmented invasive functions in the BxPC-3 cell line. Conversely, down-regulation of TG2 by small interfering RNA (siRNA) reversed the sensitivity of drug-resistant MCF-7 breast cancer cells to doxorubicin and rendered them sensitive to serum withdrawal-induced apoptosis (6, 7).

TG2 is ubiquitous and most diverse member of the transglutaminase family of enzymes (11). In addition to catalyzing Ca²⁺-dependent post-translational modification of proteins, it can catalyze Ca²⁺-independent hydrolysis of guanosine 5′-triphosphate and adenosine 5′-triphosphate. The ability of TG2 to hydrolyze guanosine 5′-triphosphate enables it to serve as a signaling molecule, leading to the activation of a cytoplasmic target, phospholipase C (12, 13). Moreover, the high affinity of TG2 for fibronectin may play a role in promoting integrin-mediated cell adhesion (14) and cell migration functions (15, 16). Similarly, TG2 has been shown to activate RhoA and mitogen-activated protein kinase pathways (MAPK; ref. 17), which control key signaling pathways that impinge on the invasive and metastatic behavior of malignant cells. Several reports have documented elevated expression of TG2 in various cancer types (7–11, 18, 19).

In this report, we examined the constitutive expression of TG2 in 75 PDAC tumors and 12 PDAC cell lines. The results were correlated with various molecular markers and clinicopathologic data. We showed that elevated TG2 expression was associated with gemcitabine resistance and invasive phenotypes in pancreatic cancers. Furthermore, we examined the molecular mechanisms by which TG2 overexpression lead to gemcitabine resistance and increased invasive potential in PDAC cell lines using adenovirus overexpression system, siRNA knockdown, and confocal microscopy. We showed, for the first time, that TG2 can interact with focal adhesion kinase (FAK) and result in its activation; this function was independent of the transamidation activity of TG2. Therefore, we concluded that elevated TG2 expression in PDAC cells can contribute to the development of drug resistance and invasive phenotypes by activation of the FAK/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.

Materials and Methods

Materials. The rabbit polyclonal antibodies to phosphorylated AKT (pAKT; Ser 473), AKT, phosphorylated extracellular signal-regulated kinase (pERK1/2), and phosphatidylinositol 3-kinase (PI3K) were purchased from Cell Signaling Technology. The BxPC-3 cell line was kindly provided by Dr. Rakesh Kumar, Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center.
(ERK) 1/2 (pERK1/2), and ERK1/2 were from Cell Signaling Technology (Beverly, MA). Mouse monoclonal antibodies (mAb) to pY397 FAK and FAK were purchased from BD Biosciences Pharmingen (San Diego, CA). Anti-TG2 mAb CUB7401 was purchased from Neomarkers (Freemont, CA). Anti-
\( \beta \)-actin antibody was from Sigma Chemical Co. (St. Louis, MO), and the goat anti-rabbit and sheep anti-mouse horseradish peroxidase were purchased from Amersham Biosciences (Piscataway, NJ). TrueBlot anti-mouse Ig IP beads were from eBiosciences (San Diego, CA). The cell fractionation kit was from Biovision, Inc. (Mountain View, CA). DMEM/F-12, RPMI 1640, keratinocyte serum-free medium, bovine pituitary extract, recombinant human epidermal growth factor (EGF), fetal bovine serum, and Normocin antibiotic were all purchased from InvivoGen (San Diego, CA).

The PDAC cell lines AspC-1, MiaPaCa-2, Panc-1, HPAF-II, Hu766T, Capan-1, Capan-2, and BxPC-3 were provided by Dr. Shrikant A. Reddy (The University of Texas M. D. Anderson Cancer Center, Houston, TX). Panc-28, Panc-02-3, Panc-48, and Su8686 cell lines were provided by Dr. Paul J. Chiao (The University of Texas M. D. Anderson Cancer Center). All cell lines were maintained in the log phase of cell growth by being cultured in RPMI 1640 or DMEM/F-12 supplemented with FCS (10%, v/v), Normocin (0.1 mg/mL), 1-glutamine (2 mmol/L), and HEPES (10 mmol/L; U.S. Biochemical, Cleveland, OH) at 37°C in a CO2 incubator. The immortalized pancreatic ductal epithelium cell line (E6E7) was provided by Dr. Ming Tsao (Ontario Cancer Institute, Toronto, Ontario, Canada) and cultured in keratinocyte serum-free medium supplemented with bovine pituitary extracts, human EGF, and FCS.

**TG2 enzymatic activity.** Cells at 70% to 80% confluence were washed in PBS and collected in a minimal volume of the lysis buffer [20 mmol/L Tris-HCl (pH 7.4) containing 1 mmol/L EDTA, 150 mmol/L NaCl, 14 mmol/L PBS, and collected in a minimal volume of the lysis buffer (20 mmol/L Tris-HCl buffer [50 mmol/L (pH 8)] containing 150 mmol/L NaCl and 1% NP40 and precleared by incubation with 50 μL Trueblot anti-mouse Ig IP beads for 1 hour at 4°C. The pellet was discarded, and the supernatant was subjected to immunoprecipitation: 200 ng cell lysate was incubated with 2 μg of specific antibody for 1 hour at 4°C. Twenty microliters of Trueblot anti-mouse Ig IP beads was added, and the pellet was further incubated on a rotating device overnight at 4°C. The pellet was then washed four times in ice-cold lysis buffer. The supernatant was discarded, and the cell lysate was resuspended in 50 μL of the sample buffer. The samples were fractionated by SDS-PAGE and analyzed by immunoblotting and autoradiography.

**Cytotoxicity.** The number of viable cells remaining after the appropriate treatment was determined by measuring their ability to reduce 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt (MTS) into a soluble formazan in accordance with the manufacturer's instructions. Logarithmically growing cells were plated at 2 × 10^4 per well in 96-well plates and allowed to adhere overnight. They were then cultured alone or with 0.1 mmol/L to 100 μmol/L gemcitabine for 24, 48, or 72 hours. Each experiment was repeated thrice in triplicate. The concentration of gemcitabine required to inhibit proliferation by 50% (IC50) was calculated. Under identical conditions, the cells were trypsinized, and the cell viability was determined with a trypan blue exclusion test to confirm the MTS results.

**In vitro invasion.** The invasive potential of PDAC cell lines was studied in vitro by determining the number of cells that invaded through Matrigel-coated Transwell polycarbonate membrane inserts as described previously (21). In brief, Transwell inserts with a pore size of 12 μm were coated with 0.78 mg/mL Matrigel in serum-free medium. Cells were recovered by trypsinization, washed, and resuspended in serum-free medium, and 0.5 mL of the cell suspension (0.5 × 10^6 cells) was added to duplicate wells. After incubation for 48 hours, the cells that passed through the filter were stained using a Hema-3 stain kit (Fisher Scientific, Houston, TX). The cells in 10 random fields were counted under a microscope.

**Wild-type and C277S mutant TG2 adenosinor.** An adenosinor containing wild-type (WT; TG2wt) or C277S mutant TG2 (TG2m) cDNA was kindly provided by Dr. Ugra Singh (The Texas A&M University System Health Science Center, Temple, TX). In brief, TG2 cDNA cloned in pcDNA3.1 vector was first subcloned in a pshuttle 2 vector and then in a BD adenoX adenoviral vector. HEK293 cells were transfected with recombinant adenoviral plasmid for packaging of adenosinor particles. The adenosinor was purified on a CsCl2 gradient and used at 25 multiplicities of infection (MOI). Cells infected with lacZ adenosinor served as the control.

**TG2 down-regulation by siRNA.** Two TG2 siRNA sequences were designed and purchased from Qiagen (Germantown, MD). A sequence that did not have homology to any human mRNA (as determined by a BLAST search) served as a control, whereas two sequences were designed to target TG2 mRNA, siRNA1 (target sequence, 5'-AAGGCCGTTTTTCCTACAAGA-3') and siRNA2 (target sequence, 5'-AAGGGCAACACCTGAATAA-3'). For transfection, 2 × 10^4 cells were plated in each well of six-well plates and allowed to adhere for 24 hours. On the day of transfection, 30 μL RNAiFect transfection reagent (Qiagen) was added to 5 μL siRNA (1 μg/μL) in a 65-μL culture medium to give a final volume of 100 μL. The siRNA/transfection reagent mixture was incubated at ambient temperature for 15 minutes and added uniformly to plates in serum-containing medium. After 48 hours of transfection, cells were recovered and used for appropriate determinations. The transfection efficiency was determined by transfecting cells in a parallel well with fluorescent siRNA and determining fluorescence uptake under the microscope.

**Confocal microscopy.** To determine the colocalization of phosphorylated FAK (pFAK) and TG2, cells were grown on glass coverslips and fixed in

---

Cancer Res 2006; 66: (21). November 1, 2006 10526 www.aacrjournals.org

Figure 1. TG2 expression in PDAC cell lines. Western blot (A) and its densitometry analysis (B) showing basal expression of TG2 protein in 12 PDAC cell lines and one immortalized normal pancreatic epithelial cell line (E6E7). Cell lines with TG2/α-actin ratio of >100% and <100% were considered high TG2– and low TG2–expressing cell lines, respectively.
Figure 2. TG2 expression is associated with gemcitabine resistance and invasive potential in PDAC cell lines. A, Western blot analysis comparing the basal expression of TG2 in three PDAC cell lines. The enzymatic activity (histograms) in three cell lines correlated with TG2 protein levels. B, the cell viability, as determined by an MTS assay, of Panc-28, MiaPaCa-2, and BxPC-3 cells after their treatment with increasing doses of gemcitabine for 24, 48, or 72 hours. IC50 of gemcitabine for the cell lines after 72 hours. C, the invasive functions of the three cell lines, as determined by their ability to invade through Matrigel-Transwell membranes, was compared as described in Materials and Methods. Representative experiments done at least twice with similar results. Columns and points, mean of quadruplicate values; bars, SD.
hematoxylin nuclear stain was used as a counterstain. Immunostaining results were evaluated and scored independently by a pathologist and laboratory personnel. TG2 expression in tumor cells was categorized as negative (low or weak cytoplasmic staining) or positive (diffuse moderate to strong cytoplasmic staining).

Statistical analysis. The clinicopathologic and follow-up data were correlated with TG2 expression. The statistical analysis was done using Fisher’s exact test and Student’s t test with SPSS software (version 12 for Windows; SPSS, Chicago, IL) and a P < 0.05 was considered significant.

Results

TG2 expression is associated with gemcitabine resistance and increased invasive potential. Western blot analysis revealed elevated expression of the TG2 protein in all 12 PDAC cell lines tested. However, no TG2 was detected in immortalized pancreatic ductal epithelial cells (E6E7; Fig. 1A and B). Interestingly, BxPC-3 and HPAF-II cell lines, which represent the well-differentiated and relatively less aggressive PDAC cell lines, expressed lower TG2 levels than did the aggressive and undifferentiated Panc-28, Capan-2, and AsPc-1 cell lines.

Based on our earlier observations that elevated TG2 expression in cancer cells contributes to the development of the drug-resistant phenotype (8, 23), we next determined whether TG2 expression in PDAC cells is related to gemcitabine resistance. We used three cell lines, Panc-28, MiaPaCa-2, and BxPC-3, which expressed different basal levels of TG2 protein (Fig. 2A). Panc-28 cells expressed highest basal level of TG2 protein and activity followed by MiaPaCa-2 and BxPC-3 cells (P < 0.05; Fig. 2A). The ability of gemcitabine to inhibit cell growth of these cell lines was inversely related to the level of TG2 expression (Fig. 2B). The high TG2–expressing Panc-28 cells showed minimal sensitivity to the gemcitabine-induced growth inhibition as determined by the MTS cell viability assay. The IC50 of gemcitabine for Panc-28 cells was one log higher (1 μmol/L) than that for MiaPaCa-2 cells (IC50, 0.1 μmol/L; P = 0.02) and approximately two logs higher than that for TG2-deficient BxPC-3 cells (IC50, 0.01 μmol/L; P = 0.001).

We next determined whether the level of TG2 expression in PDAC cells affected their invasive potential. The three cell lines that constitutively expressed different levels of TG2 (Fig. 2A) were compared for their ability to invade through Matrigel-Transwell membranes. Results shown in Fig. 2C suggested that high TG2–expressing Panc-28 cells are 3- to 4-fold more invasive than the low TG2–expressing MiaPaCa-2 and BxPC-3 cells (P = 0.0002).

To further confirm the observation that TG2 overexpression increased the invasive potential and confer resistance to gemcitabine in PDAC cells, we overexpressed the WT (TG2wt) and
catalytically inactive (TG2m) mutant of TG2 in BxPC-3 cells. TG2m lacks transamidation activity because of a point mutation in the active site cysteine residue (C277S). The results shown in Fig. 3A and B suggested that overexpression of either TG2wt and TG2m strongly promotes the invasive potential of BxPC-3 cells. Moreover, BxPC-3 cells infected with TG2wt adenoviral construct became significantly more resistant to gemcitabine-induced cytotoxicity when compared with the adenovirus alone-infected BxPC-3 cells. Together, these results suggested that overexpression of TG2 contributes not only to gemcitabine resistance but also to the invasive potential of PDAC cells, which was independent of its transamidation activity.

**TG2 induces activation of FAK and PI3K/AKT pathways.** FAK is a nonreceptor tyrosine kinase that is activated by integrin clustering and transmits adhesion-dependent signals to promote growth, survival, and invasive functions in cells. Our previous studies using breast cancer and melanoma cancer cells showed an association between TG2 and β integrins (8, 9). Therefore, in this study, we determined the significance of TG2 expression in regulation of FAK functions. First, we compared the FAK basal activity in serum-starved Panc-28, MiaPaCa-2, and BxPC-3 cells, which expressed different levels of TG2. The results shown in Fig. 3C show a direct association between levels of TG2 expression and constitutive FAK activation [phosphorylated (pY397)]. Panc-28 cells with high basal expression of TG2 had high levels of activated FAK, whereas FAK activation was lower in MiaPaCa-2 and BxPC-3 cells, which had low TG2 expression (Fig. 3C and D). Confocal microscopic analysis further supported these observations and revealed active form of FAK at focal adhesion points in TG2-rich Panc-28 cells than in low TG2–expressing MiaPaCa-2 and BxPC-3 cells (Fig. 3E). The Western blot and confocal microscopic analyses showed no significant difference in total FAK expression in Panc-28, MiaPaCa-2, and BxPC-3 cells (Fig. 3C and E). These results suggest that TG2 is associated with activation of FAK in PDAC cells.

To further delineate the relationship between TG2 and FAK, we overexpressed TG2 by infecting BxPC-3 cells with 25 MOI of an adenovirus-containing TG2 WT (TG2wt) construct. As expected, TG2 expression in infected BxPC-3 cells increased by 10- to 12-fold over the basal level as determined by Western blotting and confocal microscopy (Fig. 4A and C). Overexpression of TG2 was associated with a parallel increase in the enzyme activity (Fig. 4B) and constitutive activation of FAK in BxPC-3 cells. The infection of cells with adenovirus vector alone had no effect on TG2 expression or FAK activation. Interestingly, overexpression of TG2m, which lacks the enzyme activity, also resulted in an increase in FAK activation similar to that induced by TG2wt (Fig. 4A and B). These results suggested that TG2-mediated activation of FAK occurs independent of its transamidation activity. This was further supported by confocal microscopy data (Fig. 4C). Interestingly, the TG2-mediated activation of FAK was associated with an increase in the enzymatic activity.
colocalization of TG2 with pFAK at the focal adhesion points (Fig. 4C).

Because FAK activation results in the activation of the downstream PI3K/AKT and RAS/MAPK/ERK kinase (MEK)/ERK pathways, we next determined the effect of TG2 expression on these pathways. Western blot analysis of untreated BxPC-3 cells or BxPC-3 cells infected with either TG2wt or TG2m showed marked increase in pAKT (Ser473) in infected cells (Fig. 4A). However, no change in the levels of pERK1/2 was observed in TG2-infected or untreated cells (data not shown). These results suggest that TG2 expression, independent of its transamidation activity, can result in constitutive activation of FAK/PI3K/AKT pathway and promote the invasive function of PDAC cells.

**Down-regulation of TG2 inhibits FAK activation.** To further determine the role of TG2 in FAK activation, we used siRNA approach to down-regulate the endogenous expression in Panc-28 cells. As reported previously (8, 9), siRNA1 and siRNA2 caused 80% to 90% inhibition of endogenous TG2 protein expression in Panc-28 cells (Fig. 5A). The down-regulation of TG2 expression by siRNA resulted in inactivation of FAK (Fig. 5A). However, transfection of Panc-28 cells under similar conditions with control siRNA did not alter either TG2 expression or FAK activation (Fig. 5A). Down-regulation of TG2 in Panc-28 cells also resulted in marked morphologic changes by light microscopy (Fig. 5B): the cells appeared more cylindrical in shape and segregated than were untreated controls. More importantly, the inhibition of endogenous TG2 by siRNA induced massive cytoplasmic vacuolization after 48 hours of transfection (Fig. 5B), and the cells eventually died. In addition, the down-regulation of endogenous TG2 was associated with a profound inhibition of Panc-28 cells to invade through Matrigel-Transwell membranes (data not shown). These results clearly showed that TG2 expression plays a critical role in the constitutive activation of FAK and its downstream functions and that TG2 expression is critical for the survival of Panc-28 cells.

**Association of TG2 with FAK.** We further investigated the colocalization of TG2 with pFAK in PDAC cells. In a pull-down experiment, the immunoprecipitates of cell extracts from Panc-28, MiaPaCa-2, and BxPC-3 PDAC cells with an anti-FAK antibody revealed the presence of TG2 when the membranes were probed with anti-TG2 antibody (Fig. 6A). The association of TG2 with FAK in PDAC cells was further confirmed by reverse coimmunoprecipitation using an anti-TG2 antibody and probing with a FAK antibody (data not shown). We found no appreciable difference in total FAK expression in Panc-28, MiaPaCa-2, and BxPC-3 cells. However, Panc-28 cells, which expressed high pFAK and TG2, also showed higher degree of association between TG2 and pFAK than did the MiaPaCa-2 and BxPC-3 cells (Fig. 6A). These results suggested that a direct association between TG2 and FAK may play a role in constitutive activation of FAK.

To further delineate the role of TG2 FAK activation, we determined the localization of TG2 with FAK in soluble and membranous cellular compartments. Membranous and cytosolic fractions from Panc-28 cells were immunoprecipitated with either anti-TG2 or anti-FAK antibody and probed with both antibodies. The results shown in Fig. 6B show that ~80% of the total TG2 protein was present in the cytosolic fraction and 15% was in the membrane. Notably, the fraction of TG2 bound with FAK was higher in the membrane fraction (77%) than in the cytosolic fraction (33%; Fig. 6B). Because activated FAK is mainly localized in the cytoplasmic membrane, we speculated that TG2 in the membrane was associated with the phosphorylated form of FAK.

This contention was supported by the results of immunoprecipitation of Panc-28 cell extracts with an anti-pFAK (pY397) antibody. As shown in Fig. 6C, TG2 is indeed associated with pFAK. The results of a confocal microscopy analysis (Fig. 6D) further supported the colocalization of TG2 with pFAK, particularly at the focal adhesion points. The colocalization of TG2 and pFAK at focal points was quantified in 40 cells, showing a mean number of 6.2 overlaps at focal points per cell. These results show, for the first time, that there is a direct association between TG2 and the signaling molecule FAK and that this association plays an important role in FAK activation.

**TG2 expression in PDAC tumor samples.** To further evaluate the significance of our *in vitro* observations that TG2 expression results in gemcitabine resistance and invasive potential, we examined the expression levels of TG2 in a human tissue microarray containing 75 PDAC tissue samples. We found high basal levels of TG2 expression in 42 of the 75 (56%) tumor samples
studied (Fig. 7A). However, only 24 of 70 (34%) cases showed cytoplasmic staining in benign pancreatic ducts. TG2 expression was significantly higher in PDACs compared with normal ducts \((P = 0.012)\). No staining was observed in sections treated with the isotypic control IgG instead of the primary anti-TG2 antibody. These data further supported our observations that TG2 overexpression increases the invasive potential of PDAC cell lines. A Kaplan-Meier estimate of survival in relation to TG2 expression showed no significant difference in TG2-positive patients \(n = 42\) and TG2-negative patients \(n = 33\); \(P = 0.159\) (Fig. 7B).

**Discussion**

Our data show that a significant majority of PDACs and PDAC cell lines express elevated levels of the multifunctional protein TG2. We provide the first evidence that TG2 is closely associated with FAK and results in its activation \((pFAK)\) and activation of the downstream PI3K/AKT cell survival signaling pathway. TG2 expression in PDAC cell lines was associated with increased resistance to gemcitabine and an invasive phenotype. Furthermore, we found significant association between TG2 expression and nodal metastasis, lymphovascular invasion, and late clinical stage in PDAC tumor samples.

Previously, we found that constitutive expression of TG2 in drug-resistant and metastatic breast cancer \((8)\) and late-stage melanoma \((9)\) was up-regulated. Importantly, down-regulation of TG2 expression was associated with the increased sensitivity of cancer cells to apoptotic stimuli and reversal of the drug-resistant phenotype \((8)\). Han and Park \((23)\) reported similar results in the drug-resistant lung cancer cell line PC-14/ADR. These authors showed that the acquisition of multidrug resistance in PC-14 cells was associated with a 10- to 15-fold increase in TG2 expression and that inhibition of TG2 expression by TG2-specific antisense or ribozyme rendered the cells sensitive not only to multidrug resistance–related drugs but also to other anticancer drugs.

In this study, we determined the constitutive TG2 expression status of PDAC tumors and tumor cell lines. Of the 12 PDAC cell lines tested, 10 expressed high levels of TG2 protein, and two expressed moderate levels (Fig. 1). Importantly, 56% of the PDAC tumor samples showed elevated levels of TG2, which was associated with nodal metastasis, lymphovascular invasion, and late clinical stage. In cell lines, TG2 expression was associated with resistance to gemcitabine (Fig. 2B), a commonly used drug for the treatment of pancreatic cancer. Similarly, high TG2 expression was associated with invasive behavior (Fig. 2C). Thus, ectopic expression of TG2 in BxPC-3 cells rendered the cells highly invasive (Fig. 4D) and resistant to gemcitabine and, conversely, the inhibition of TG2 by siRNA significantly attenuated the invasive potential of Panc-28 cells.

To delineate the possible mechanism by which TG2 could promote chemoresistance and invasive potential in PDAC cells, we studied the relationship between TG2 and FAK. TG2 has been shown to promote FAK activation via its ability to promote the integrin-mediated attachment of cells to fibronectin \((8, 14)\), a major...
FAK is a nonreceptor cytoplasmic protein tyrosine kinase that provides signaling and scaffolding functions at sites of integrin adhesion. Ample evidence supports the role of FAK in cell adhesion, cell migration, and cell cycle progression (24). Increased FAK expression is frequently associated with malignant or metastatic disease and poor patient prognosis (24–30). FAK expression is increased in various tumors, such as those of the breast, colon, thyroid, head and neck, ovaries, liver, esophagus, and pancreas (24–30). The activated form of FAK constitutes tyrosine phosphorylation at the COOH terminus (Y397). This results in the phosphorylation of other tyrosine residues (Y397, Y407, Y576, Y577, Y861, and Y925), leading to the activation of several downstream signaling pathways, such as RAS/ERK, PI3K/AKT, and Crk/Dock180/Rac (ref. 24 and references therein).

The data presented here suggest a novel pathway that could lead to the constitutive activation of FAK in pancreatic and possibly other aggressive cancer cells. TG2 was closely associated with FAK protein. The interaction of TG2 with FAK was associated with FAK autophosphorylation (pY397; Fig. 4). Indeed, ectopic expression of TG2 in BxPC-3 cells resulted in enhanced FAK activation (Fig. 4C) and FAK colocalization with TG2 in the focal points (Fig. 6D). Conversely, the inhibition of TG2 by siRNA inhibited FAK activation in Panc-28 cells (Fig. 5A). The major fraction of activated FAK was localized in the membrane in complex with TG2 (Fig. 6B).

The ability of TG2 to associate with FAK and subsequent phosphorylation of FAK were independent of TG2 transamidation activity, as suggested by the observation that the expression of catalytically inactive point-mutated (C277S) TG2 could result in a similar association and activation of FAK (Fig. 4A). Together, our results suggest a role for TG2 in FAK autophosphorylation that is mediated by a direct association between the two proteins. How the association of TG2 with FAK affects autophosphorylation of FAK remains a matter of speculation. Indeed, it is well known that the recruitment of FAK and its association with the cytoplasmic tails of integrins result in its autophosphorylation (24). Similarly, it is likely that the conformational changes induced in FAK in response to its interaction with TG2 can result in its autophosphorylation. Alternatively, the association of TG2 with pFAK might protect it from the action of endogenous phosphatases, such as PTEN (31). We are currently investigating these and other possibilities to determine the mechanisms that underlie the phosphorylation of FAK in response to its interaction with TG2.

Furthermore, TG2-mediated FAK activation was associated with the activation of PI3K/AKT pathway but had no effect on the RAS/MEK/ERK pathway (Fig. 4A). These observations are supported by an earlier report by Kang et al. (32) who showed that overexpression of TG2 in human chronic myelogenous leukemia (K562) cells was associated with activation of the PI3K/AKT signaling pathway (33). The significance of the PI3K/AKT pathway to the overall therapeutic strategy for PDAC treatment remains to be established. The results of this study provide a novel target for the development of therapeutic agents that could lead to the selective inactivation of FAK in pancreatic cancer cells.
in conferring an aggressive phenotype to cancer cells has been well established (32, 34, 35). Indeed, our earlier studies with drug-resistant and metastatic breast cancer cells revealed that downregulation of TG2 expression renders the cells sensitive not only to anticancer drugs but also to stress-induced apoptosis (8, 9). In the present study, the inhibition of endogenous TG2 by siRNA induced a massive accumulation of cytoplasmic vacuoles (Fig. 5B) that eventually led to the death of Panc-28 cells via autophagy.5

Overall, the results of our study show that elevated expression of TG2 in PDAC tumor cells and cell lines contributes to increased cell survival and invasive functions. One mechanism that likely contributes to these effects is the ability of TG2 to associate with and activate FAK, resulting in the activation of its downstream prosurvival PI3K/AKT signaling pathway. In conclusion, our results suggest that TG2 could be an attractive target for anticancer therapeutics, and they provide a strong rationale for developing TG2 inhibitors to target the disruption of TG2-FAK protein-protein interactions.

Acknowledgments


Grant support: NIH grants CA992115 (K. Mehta), CA98823, and CA98823 (B. Manavathi and R. Kumar) and a Specialized Program of Research Excellence grant P20CA101936 in Pancreatic Cancer at The University of Texas M.D. Anderson Cancer Center.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Ann M. Sutton for editorial help.

References

Increased Expression of Tissue Transglutaminase in Pancreatic Ductal Adenocarcinoma and Its Implications in Drug Resistance and Metastasis


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/21/10525

Cited articles
This article cites 34 articles, 11 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/21/10525.full.html#ref-list-1

Citing articles
This article has been cited by 27 HighWire-hosted articles. Access the articles at:
/content/66/21/10525.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.